Tavneos is manufactured by California-based ChemoCentryx, Inc., a biopharma company focused primarily on orphan and rare diseases.
ANCA-associated vasculitis is a rare systemic disease in which over-activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels.
This results in organ damage and failure, with the kidney as the major target, and is fatal if not treated.
Through this partnership, Amber Specialty Pharmacy's best-in-class service model will support autoimmune specialists, rheumatologists and patients throughout the country.
Amber Specialty Pharmacy is one of two specialty pharmacies selected by ChemoCentryx to dispense Tavneos as part of a limited distribution network.
Amber Specialty Pharmacy, a Hy-Vee, Inc. subsidiary, is in the specialty pharmacy industry with more than 20 years of experience providing specialized care for persons with chronic, complex medical conditions.
Amber Specialty Pharmacy is accredited by the Utilization Review Accreditation Commission and the Accreditation Commission for Health Care.
Amber Specialty Pharmacy headquarters are located in Omaha, Nebraska, with an additional 20 locations throughout the United States and Puerto Rico. Amber Specialty Pharmacy was named the 2020 Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins